Based on the high-dose data, AC Immune intends to advance to later-stage development of ACI-35.030, which according to the company is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. The company also plans to launch clinical studies of the optimized ACI-24 during the first half of this year . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge